Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities

Use of maximal dosage renin-angiotensin-aldosterone system inhibitors in a real life population of complicated type 2 diabetes – contraindications and opportunities

Abstract Objective Pharmacological inhibition of the renin-angiotensin-aldosterone-system (RAASi) is the cornerstone of hypertension treatment, renoprotection and secondary prevention of cardiovascular disease in patients with type 2 diabetes. Although there is a dose-dependent effect of RAASi with...

Full description

Bibliographic Details
Main Authors: C. M. Gant, M. M. Oosterwijk, S. H. Binnenmars, G. J. Navis, H. Haverkate, S. J. L. Bakker, G. D. Laverman
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Nephrology
Subjects:
Type 2 diabetes
Cardiovascular disease
RAAS inhibition
Chronic kidney disease
Real world data
Online Access:https://doi.org/10.1186/s12882-023-03205-2

Internet

https://doi.org/10.1186/s12882-023-03205-2

Similar Items